Member Info for Toukankahmoon

IceCool

You belittle the article because it doesn’t agree with with your overinflated views of Avacta and for that matter yourself. It deals in facts and not what might happen if/when the clinical trials deliver large scale irrefutable evidence of efficacy. To me it helps explain why the share price is currently hovering around 70-80p.

As to the FDA’s current view/policy, most on here are incredulous that this didn’t happen 2 years ago given the safety profile and an understanding of the mechanism and therefore why there is little collateral damage.

CJ62

You are obviously such a charming person it would be lovely to meet you.

Any attempt by me to be courteous ends up as a . . .

. . . oh and I know of at least one other large investor in Avacta who will be there.

Another great car meet today. I love the summer.

For anyone actually interested in my wellbeing and living in the Northwest, I will be showing cars at UK’s biggest American car show at Tatton Park Knutsford next weekend. I’d love to meet you.

IceCool

I don’t have any issue with Avacta’s long term potential.

BV and others yes we need the AVA6000 1b trial to carry on to prove PFS.

I’ve no argument against this. However I still stand by my statement that the article that sparked this spate of name calling was a very thorough and balanced analysis of where we are right now now

BTW either Sheppyhas 25 aliases on here or there are some very juvenile posters

You know I’m not gonna do that. It’s far more fun watching you twist and squirm trying to see every RNS from Avacta as unexpectedly excellent while the real world has a more down to earth view. And when you are faced with facts you just resort to the usual bullying

So what makes you a better judge of Avacta than a professional financial journalist?

Which points in the article are not true facts

Is CC now lying when she says she isn’t going to progress AVA6000 without a partner?

I could add many more but you are too much in love to hear.

Let’s face it, any reasoned analysis of Avacta is going to upset some rampers on here. Because of course they are privy to more information than the person who wrote that article. Couldn’t possibly be that they are biased. The article does attempt to give reasons why the SP is where it is. All we get from the fan club is because it’s being manipulated, BP haven’t heard of what we are achieving, AIM is crap, thick as mince and various other spurious and less believable reasons. But hey ho twas ever thus.

. . . or READ this even 🤣

Lovable

Excuse me for reposting this, but it is such a good summary and the rampers are so determined to drown it out over the true definition of “cure”.

EVERYONE SHOULD TEAD THIS

https://business-news-today.com/avacta-just-won-a-clean-fda-path-to-full-ava6000-approval-so-why-did-avct-barely-move/

When do you think P2 will start?

Lovable

THE ARTICLE YOU POSTED IS A GREAT EVENHANDED AND THOROUGH EXPLANATION

EVERYONE SHOULD READ IT. IT WOULD STOP ALL THE POINTLESS RAMPING ON HERE.

Pointless discussing this with you. And doesn’t alter the fact that if AVA6000 or AVA6103 get approved quickly they will be a Godsend to cancer sufferers

VS

No chemo treatment is a cure. There is always the chance of a recurrence because it is only tackling the symptoms not the root cause. Some patients will remain cancer free until they die of old age, others sadly won’t be as lucky. That is why BP are pumping so much money into immunotherapy/gene therapy.

But what Avacta is doing is a massive improvement.

Oneknows

The fact that the current product line isn’t a cure for cancer doesn’t make it any less useful - at least until other approaches catch up. And even then as a first line of attack the tumour killer with no side effects will obviously be a success.

If you take the time to read my posts then you would see:

I believe the mechanism works

I think that AVA6000, etc will be successful but not “next week” like the ludicrous rampers keep predicting

Consequently I have held a large (for me) number of shares for years. I am not buying at the moment because in the short term I can make more money. For instance the shares I bought in EasyJet in April are doing exceedingly well. Just need to time my exit.

Unlike some others on here I try to continually reassess the risk/reward balance of my punts.

But I will always challenge fake news on here. AVA6000 is not a cancer cure.

BV

“How do you know they don’t offer a cure”

. . . because they kill the tumour, they don’t prevent tumours or tweak the body’s immune system to automatically attack tumours. But future payloads, who knows?🤞

BTW

None of Avacta’s products at the moment offer a cancer cure. Future drugs with different payloads might but ATM I think you are get confused with gene therapies that are being developed.

I get lambasted for my predictions and HarChris remembers every little one and takes great pleasure in reminding me of them . . . . then you get an absolutely baseless set of ramping predictions that fly in the face of all evidence and the rampers lap it up. Says so much about this BB.

Yes. Hit the nail on the head. It’s “criminal” that nobody at the FDA understood the science well enough to make this call 2 years ago

We all invested here because Avacta isn’t a one trick pony. Of course the mechanism will be the basis for many products both Avacta developed and licensed out.

CC wants to keep the reins so no TO

But I really can’t see a dual NASDAQ listing until a pivotal event precipitates a rerate. There would be significant dilution. Of course at the right time Avacta could just quit the UK, leave AIM behind. Then the rampers would be happy